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Abstract 
Background: Cryopreserved peripheral blood mononuclear cells (PBMCs) are commonly collected in biobanks. How‑
ever, little data exist regarding the preservation of tumor‑associated cells in cryopreserved collections. The objective of 
this study was to determine the feasibility of using the CellSieve™ microfiltration assay for the isolation of circulating 
tumor cells (CTCs) and circulating cancer‑associated macrophage‑like cells (CAMLs) from cryopreserved PBMC samples.
Methods: Blood samples spiked with breast (MCF‑7), prostate (PC‑3), and renal (786‑O) cancer cell lines were used to 
establish analytical accuracy, efficiency, and reproducibility after cryopreservation. The spiked samples were processed 
through Ficoll separation, and cryopreservation was followed by thawing and microfiltration.
Results: MCF‑7 cells were successfully retrieved with recovery efficiencies of 90.5 % without cryopreservation and 
87.8 and 89.0 %, respectively, on day 7 and day 66 following cryopreservation. The corresponding recovery efficiencies 
of PC‑3 cells were 83.3 % without cryopreservation and 85.3 and 84.7 %, respectively, after cryopreservation. Recovery 
efficiencies of 786‑O cells were 92.7 % without cryopreservation, and 82.7 and 81.3 %, respectively, after cryopreserva‑
tion. The recovered cells retained the morphologic characteristics and immunohistochemical markers that had been 
observed before freezing. The protocols were further validated by quantitation of CAMLs in blood samples from two 
patients with renal cell carcinoma (RCC). The recovery rates of CTCs and CAMLs from cryopreserved samples were not 
statistically significant different (P > 0.05) from matched fresh samples.
Conclusions: To our knowledge, this is the first report that CAMLs could be cryopreserved and analyzed after 
thawing with microfiltration technology. The application of microfiltration technology to cryopreserved samples will 
enable much greater retrospective study of cancer patients in relation to long‑term outcomes.
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Background
Circulating tumor-associated cellular structures, such as 
circulating tumor cells (CTCs) and circulating cancer-
associated macrophage-like cells (CAMLs) in blood, 
have emerged as important prognostic and predic-
tive biomarkers for diagnosis, prognosis, and manage-
ment of cancer diseases [1–6]. A blood based biopsy 
has advantages over traditional tissue biopsy, including 
lower cost, reduced risk, and repeatability. These assays 
are usually performed on fresh blood samples within 
a limited timeframe after blood draw. Little is known 
about the effects of cryopreservation on the recovery and 
characterization of all types of tumor-associated cells. 
Furthermore, assays compatible only with fresh samples 
require clinical on-site processing, because many factors, 
including sample transportation, age of blood, tempera-
ture fluctuations, and preservative reagents, can affect 
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Prospective cryopreservation is a common method for 
long-term storage of biospecimens and is an invaluable tool 
for retrospective clinical studies of selected populations [7–
9]. However, these biospecimens may be incompatible with 
assays that require intact cell membranes, because of ice 
crystal formation and subsequent lysis during the thawing 
process. Thus, assays compatible with current cryopreser-
vation methods would allow the retrospective analysis of 
biomarkers in patient cohorts with known clinical out-
comes. Additional advantages include (1) performing the 
assay in batches in a centralized laboratory to minimize 
interlaboratory variations and (2) assaying longitudinal col-
lections together to minimize interassay variations.
Microfiltration is an effective method for isolating 
CTCs and other cells of interest from several types of 
cancers [1–3, 10–14]. CellSieve™ microfiltration technol-
ogy, developed by Creatv MicroTech, Inc, uses a novel fil-
ter membrane with a high density of evenly distributed 
pores (160,000 pores per filter) with precisely controlled 
pore size (7  µm) to achieve high capture efficiency of 
tumor cells and low contamination of blood cells. The 
membrane material has low background fluorescence 
that allows the cells to be further characterized through 
various fluorescence-based assays.
The objective of our study was to determine whether 
CellSieve™ microfiltration technology can be applied to 
recovery and analysis of CTCs and CAMLs from cryo-
preserved PBMC samples. Initially, we used blood sam-
ples spiked with three cancer cell lines, MCF-7, PC-3, 
and 786-O, to demonstrate technical feasibility of the sys-
tem. The protocols were validated by analyzing CAMLs 
recovered from cryopreserved PBMC samples of patients 
with renal cell carcinoma (RCC).
Methods
Cell lines and reagents
786-O (renal cell carcinoma), MCF7 (breast cancer), PC-3 
(prostate cancer), SKBR3 (breast cancer), MDA-MB-231 
(breast cancer), LNCaP (prostate cancer), and primary 
HUVEC (human umbilical vein endothelial cells) cell 
lines and others as previously described [1, 2, 15] were 
all obtained from American Type Culture Collection 
(ATCC). The cell lines were cultured using conditions 
specified by ATCC protocols. Cell suspensions were pre-
pared with standard trypsin-treatment methods. Total 
cell counts were determined manually with a hemocy-
tometer. Cell viability was assessed with trypan blue dye 
exclusion assay. Fresh cells with viability greater than 
98 % were used for spiking experiments. CellSieve™ CTC 
Enumeration Kits (Creatv MicroTech, Inc) were used for 
recovery and fluorescence antibody staining of the filter-
captured cells. These kits contain CellSieve™ filter mem-
branes and reagents required for microfiltration of blood 
and/or PBMC samples and characterization of the filter-
captured cells, including ready-to-use prefixation buffer, 
postfixation buffer, permeabilization buffer and mounting 
solution with DAPI (4′,6-diamidino-2-phenylindole), and 
antibody cocktail mixtures at optimized concentrations. 
To stain breast or prostate cancer cells, antibody mixture 
containing cytokeratin (CK) 8, 18, 19/fluorescein (FITC), 
epithelial cell adhesion molecule (EpCAM)/phycoeryth-
rin (PE), CD45/Cyanine 5 was used. To stain RCC cells, 
antibody mixture containing CK8, 18, 19/FITC, vimentin/
eFluor® 615 (EF615) and CD45/Cyanine 5 was used.
Patient eligibility and recruitment
Subjects eligible for enrollment in the Multidisciplinary 
Genitourinary Diseases Biospecimen Bank were those 
seen at Mayo Clinic’s campus in Scottsdale, Arizona, and 
were ≥18  years of age, able to provide informed con-
sent, and undergoing evaluation to determine eligibility 
as a kidney donor or for treatment of genitourinary dis-
eases. During the course of routine clinical visits at Mayo 
Clinic, subjects were consented to participate in the Bio-
specimen Bank. The protocol for collecting biospecimens 
was approved under a Mayo Clinic Institutional Review 
Board (IRB) approved protocol (08-000980). For healthy 
control subjects, blood samples were collected at Creatv 
MicroTech from healthy donors signed informed consent 
under a protocol approved by the Western IRB.
CellSieve™ microfiltration platform
The CellSieve™ microfiltration platform has been devel-
oped by Creatv MicroTech [1, 2, 15]. This platform consists 
of three basic components: a filter membrane and cartridge 
(Creatv MicroTech, Inc), and a programmable syringe pump 
system (KD Scientific). The filter membrane has a 9-mm 
diameter filtration area containing a high density of pores 
(approximately 160,000 pore density and 7-µm pore size). 
Figure  1a shows a scanning electron microscope (SEM) 
image of the filter and Fig.  1b illustrates a schematic dia-
gram of assembling the microfilter into the filter cartridge. 
The assembled cartridge is connected to an input syringe 
with an inlet fitter to introduce the blood sample and a 
waste syringe to generate negative pressure. This assem-
bly was installed on the syringe pump. The syringe pump 
is programed to pull to deliver a selected flow rate of blood 
through the microfilter. After filtration and washes, the 
syringe barrel and inlet fitting are removed. The remaining 
parts of the cartridge are used as a reaction chamber, allow-
ing for performing assay steps directly within the chamber. 
Reagents were added into the chamber with pipetting and 
drawn into the waste syringe by the syringe pump.
Compared with conventional microfiltration methods, 
the CellSieve™ microfilter membrane provides (i) precise 
uniform pore size and distribution for maximal filtration 
Page 3 of 12Zhu et al. J Transl Med  (2016) 14:198 
efficiency, (ii) high porosity for fast filtration process, (iii) 
low background allowing high quality images, (iv) flat 
surface on the microscope slide minimizing the need for 
refocusing during microscopy, and (v) strong material to 
avoid breakage. To eliminate unnecessary handling pro-
cedures, such as filter disassembly for immunofluores-
cence, a filter cartridge is designed to aid in processing 
sample microfiltration followed by on-cartridge assay 
procedures; all of the assay procedures including anti-
body staining can be completed within the cartridge. 
With multiple cartridges, multiple blood samples can be 
analyzed simultaneously. Furthermore, the use of a pro-
grammable syringe pump provides consistent flow rate. 
The overall sample processing time is less than 2.5 h.
Microfiltration of healthy blood samples spiked with cell 
lines
Samples of whole blood were collected from healthy 
donors into sodium heparin Vacutainer tubes (Becton, 
Dickinson and Co). Separation of PBMC was performed 
with Ficoll-Paque (GE Healthcare) according to the pro-
tocols used in Mayo Clinic’s biobank for processing clini-
cal samples [8]. 7.5 mL of whole blood was centrifuged at 
1600 rpm for 15 min. Plasma was removed and replaced 
with the same volume of phosphate buffered saline 
(PBS). A cell suspension was prepared by 1:1 diluted 
the cell sample with PBS. Ten mL of Ficoll-Paque solu-
tion (GE-Healthcare) was added in a 50 mL conical tube. 
The diluted cell suspension was then slowly and carefully 
layered on the top of Ficoll-Paque solution without mix-
ing. The sample was centrifuged at 400×g for 30 min at 
20  °C in a swinging bucket rotor with brake-off. Imme-
diately after centrifugation, the upper layer was aspirated 
and discarded. The mononuclear cell layer was carefully 
transferred to a new 15-mL conical tube and mixed with 
PBS to a total of 15 mL. The sample was centrifuged at 
300×g at room temperature for 10  min with brake-on. 
The supernatant was removed and discarded. The PBMC 
was gently washed one more time with PBS. The cells pel-
let was resuspended in 1 mL of cryogenic medium (10 % 
dimethyl sulfoxide and 90  % fetal bovine serum), and 
transferred into a Nunc (Sigma-Aldrich Co LLC) cryo-
vial. The tubes were placed on Mr. Frosty tube racks and 
immediately placed in dry ice (less than 10 min at room 
temperature). The cryovials on the rack were directly 
stored at −80 °C freezer overnight. The frozen cryovials 
were transferred and placed in liquid nitrogen if it was 
needed.
For spiking experiments, a defined number of live 
tumor cells were spiked into the blood samples. The 
spiked samples were subjected to Ficoll separation to 
isolate fractions containing PBMCs and tumor cells. The 
mononuclear cells were washed, suspended in 1  mL of 
cryogenic medium, and transferred into a Nunc cryovials 
(1 mL/vial). For each cell line, four vials of sample were 
prepared. One vial was used as a control, with no cryo-
preservation. The other three vials were stored at −80 °C 
until thawed. After a period of storage, the frozen sam-
ples were quickly thawed in a 37 °C water bath, followed 
by immediate processing through CellSieve™ microfil-
tration in accordance with Creatv MicroTech’s protocol. 
Briefly, the filter membrane was rinsed with 5 mL of PBS. 
Each of the cell samples was washed, prefixed, and then 
filtered through the filter membrane (flow rate, 5  mL/
min). The filter membrane was washed five times with 
PBS. The cells on the membrane were further treated 
with postfixation and permeabilization buffers (Creatv 
MicroTech, Inc.).
To stain recovered MCF-7 and PC-3 cells, we added 150 
µL of fluorescent antibody mixture, against cytokeratins 
8, 18, 19/FITC, EpCAM/PE, and CD45/Cyanine5, and 
incubated the samples at room temperature for 1  h. To 
stain recovered 786-O cells, fluorescent antibody mixture 
against cytokeratins 8, 18, 19/FITC, Vimentin/EF615, 
and CD45/Cyanine5 was used. Unbound antibodies were 
washed away with PBS.
After completion of the assay, the filter cartridge was 
disassembled and the filter membrane removed and 
placed onto a clean microscope slide, then mounted 
with 10  µL of mounting solution with DAPI and a 
cover slip for microscopy examination. The positivity 
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Fig. 1 Schematic representation of assembly and setup of the Cell‑
Sieve™ Microfiltration System. a Microfilter membrane. b Assembly of 
the filter cartridge
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fluorescence signal greater than threefold over the back-
ground. The majority of cells were the single cells. For a 
cluster of small number of cells that were aggregated into 
a clump, we counted each cluster as one cell. The recov-
ered tumor cells were counted from five fields of view 
under the 10× objective covering about 5 % of the filter 
area, and an average was calculated for estimating the 
total number of cells on the entire filter membrane.
Microfiltration of blood samples collected from patients 
affected by metastatic renal cell carcinoma
Whole blood samples, with three matched tubes for 
each blood draw, were collected in CellSave tubes (Jans-
sen Diagnostics, LLC) from patients with RCC at Mayo 
Clinic and shipped to Creatv MicroTech for analysis. The 
concordance of the recovery was determined through 
processing of the matched tubes as with cryopreserva-
tion and without cryopreservation, respectively. Two of 
the tubes labeled as without cryopreservation (Tube 1 and 
Tube 2) were processed through CellSieve™ microfiltration 
within 24 h after blood draw. The third tube was processed 
through Ficoll separation, cryopreservation at −80 °C for 
7  days, followed by thawing and CellSieve™ microfiltra-
tion, and antibody staining. The procedures of micro-
filtration and antibody staining were the same as used in 
the spiking experiments. The filter-captured cells from the 
Tubes 1 and 3 were stained with an antibody mixture con-
sists of fluorescent dye-conjugated antibodies against CK8, 
18, 19/FITC, vimentin/EF615 and CD45/Cyanine5. The 
filter-captured cells from the Tube 2 were stained with an 
antibody mixture consists of fluorescence-conjugated anti-
bodies against PD-L1/Alexa Fluor 488, vimentin/EF615 
and CD45/Cyanine5. The CTC was defined as a nucleated 
cell with positive staining for CKs and vimentin but nega-
tive staining for CD45 for Tubes 1 and 3. The CAML was 
defined according to criteria described previously [2].
Results
Recovery of spiked cell lines in cryopreserved human 
PBMC samples
To determine whether tumor cells could be isolated from 
cryopreserved biospecimens, whole blood cell samples 
from healthy donors were spiked with a defined num-
ber of three tumor cell lines (MCF-7, PC-3, and 786-O). 
The fractions of PBMCs and tumor cells were isolated by 
Ficoll separation and after thawing, processed with Cell-
Sieve™ microfiltration at different time points. To evalu-
ate stability of tumor cells under frozen conditions and 
whether freeze/thaw procedures affect recovery of tumor 
cells, we selected 3 time points: day 0, day 7, and day 66. 
The day 0 sample (fresh) was processed through micro-
filtration immediately without cryopreservation. The day 
7 and day 66 samples were cryopreserved at −80  °C for 
7 and 66  days and then thawed for the microfiltration 
assay. The recovered MCF-7 and PC-3 cells were identi-
fied by expression patterns of CKs+/EpCAM+/CD45−, 
whereas the recovered 786-O cells were identified by 
CKs+/vimentin+/CD45−. The results of recovery effi-
ciencies are summarized in Table 1.
We obtained mean (standard deviation, SD) spike-in 
recovery rates of 89.1 (1.0) % for MCF-7, 84.4 (1.4) % for 
PC-3, and 85.6 (6.2)  % for 786-O, respectively. Between 
the fresh and stored frozen samples, we observed that 
the cryopreservation/thaw procedure had no signifi-
cant effect on the recovery efficiencies of MCF-7, PC-3 
or 786-O cells (P > 0.05 by 2-way analysis of variance). A 
10  % decrease in recovery rates of 786-O was observed 
from the frozen samples (Day 7, 82.7 %; Day 66, 81.3 %) 
compared with the fresh sample (Day 0, 92.7 %). The cell 
line results suggest that the cryopreservation procedure 
preserves CTCs for microfiltration with minimal loss.
To determine the lowest number of tumor cells that 
can be detected by the microfiltration system, a series 
of spiking experiments were performed using six repre-
sentative cell lines (786-O, MCF7, PC-3, SKBR3, MDA-
MB-231, LNCaP). In our spiking experiments, the lowest 
absolute number of cells detected in our system was 3, 
9, 5, 5, 4, and 4 cell using 786-O, MCF7, PC3, SKBR3, 
MDA-MB231, and LNCaP cell lines, respectively.
The linearity and limit of tumor cell detection in the 
spiking experiments are shown in Additional file 1: Figure 
S1. To also determine if cells lacking genome wide chromo-
somal rearrangements or aneuploidy can be detected by 
the microfilitration system, we used primary HUVECs for 
Table 1 Recovery efficiency of spiked tumor cell lines in cryopreserved human PBMC samples
a Day 0, before freezing
b Day 7 and day 66, after freezing
Cell line Input cells Day 0a Day 7b Day 66 Mean (SD) %












MCF‑7 4000 3620 90.5 3510 87.8 3560 89.0 89.1 (1.4)
PC‑3 3000 2500 83.3 2560 85.3 2540 84.7 84.4 (1.0)
786‑O 3000 2780 92.7 2480 82.7 2440 81.3 85.6 (6.2)
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spiking experiments. Similar to MCF-7, PC-3 and 786-O, 
our observed capture efficiency for HUVECs was greater 
than 94 % (Additional file 2: Table S1). Microfiltration did 
not impact the expression of endothelial markers (Addi-
tional file 3: Figure S2). We also investigated the effect of 
storage temperatures at −80 °C and in liquid nitrogen on 
PBMC samples. No significant differences in cell morphol-
ogy and antibody staining patterns were observed between 
cells cryopreserved (at −80 °C) and in liquid nitrogen for 
three weeks (Additional file 4: Figure S3).
Expression of epithelial and mesenchymal biomarkers 
in processed cryopreserved tumor cell lines
To determine if cryopreservation alters tumor cell lines, 
the concordance of tumor cell morphologies, as well as 
antibody staining patterns of the epithelial and mesen-
chymal markers, was compared among the samples that 
were processed with or without cryopreservation. No 
damage, as evidenced by loss of markers, was observed in 
the recovered cells. The recovered cells retained the mor-
phologic characteristics and markers that were observed 
before freezing (Fig. 2). The signal and staining patterns 
of cytokeratins, EpCAM, and vimentin were largely 
unchanged after cryopreservation. We did not observe 
any notable differences in staining patterns and staining 
intensity among the fresh (day 0) specimens vs the frozen 
specimens (day 7 and day 66). These results confirm that 
the cytokeratin, EpCAM, and vimentin markers, as well 
as cell morphologic characteristics, are preserved in the 
cryopreserved tumor cells.
Recovery and enumeration of CAMLs in RCC patient 
samples processed with and without cryopreservation
In a prior study, we identified CAMLs in peripheral 
blood from patients with various solid tumor cancers 
[2]. To determine whether detection of CAMLs is com-
patible with cryopreservation, three blood samples were 
collected from a patient affected by stage IV RCC with 
sarcomatoid differentiation with the primary kidney can-
cer in place and soft tissue metastases (RCC Patient 1). 
This patient was selected for study because the samples 
were known to contain CAMLs defined using criteria 
from our prior study [2]. Blood samples were collected 
at three different time points (days 0, 40, and 60). Prior 
to systemic therapy, the CAML enumeration was high-
est at 13 per tube. After initiation of systemic therapy, 
the CAML enumeration decreased to two per tube. At 
the time of progression on systemic therapy and prior to 
death, the CAML enumeration increased to 4 per tube. 
Three matched blood tubes were drawn at defined time 
points during the treatment course. Tube 1 and Tube 2 
were processed through the standard microfiltration pro-
cedures without cryopreservation (fresh), whereas Tube 
3 was processed through Ficoll separation, cryopreserva-
tion, thaw, and microfiltration (frozen). Typical CAMLs 
were detected in both samples without cryopreservation 
(fresh) and the matched sample after cryopreservation 
(frozen) (Table 2; Fig. 3).
We did not detect statistically significant differences 
in CAML enumeration among the fresh vs frozen spec-
imens (P  >  0.05 by 2-way analysis of variance). We also 
measured the signal intensities of CKs in the cells from 
the Tube 1 and Tube 3. The Tube 2 was not used for anal-
ysis of signal intensity because it was not stained with 
CKs. All of the images for CKs were taken under a con-
sistent exposure time (600 ms). Three cytoplasmic posi-
tions were selected for measurement of signal intensities 
of CKs in each CAML, representing the high, majority, 
and low signals of CKs. The CK signals were plotted ver-
sus each CAML cells (Additional file  5: Figure S4). The 
high and low signals of CKs were indicated as error bars. 
The background signal of the filter membrane, shown 
as a dotted line in the plot, was an average signal meas-
ured from the fourteen locations on the filter membrane. 
At Time Point 1, the majority of CK signal intensi-
ties in the fresh CAMLs (in range of 460–850, average 
616.43 ± 97.72) were similar to that in the frozen CAMLs 
(range of 522–886, average 619.00  ±  100.71), suggest-
ing that the CKs were preserved after the cryopreserva-
tion. At Time Points 2 and 3, the CK signals in the fresh 
CAMLs were slightly higher than that in the frozen 
CAMLs. We did not measure the signals of vimentin 
because different exposure times were used in the imag-
ing to avoid signal saturation.
(See figure on next page.) 
Fig. 2 Recovery of tumor cell line cells in cryopreserved peripheral blood mononuclear cells (PBMCs) samples. Healthy blood samples were spiked 
with three tumor cell lines: MCF‑7 (a), PC‑3 (b), and 786‑O (c). The PBMCs and tumor cells were isolated with Ficoll separation and then cryopre‑
served. The tumor cells were retrieved after thawing through CellSieve™ microfiltration. Day 0 (fresh) was a control sample without cryopreserva‑
tion. Day 7 and day 66 (frozen) were the samples after cryopreservation. Each biomarker expression is indicated as CK8, 18, 19/FITC (green), EpCAM/
PE (orange), vimentin/EF615 (red), and CD45/Cyanine5 (magenta). a The MCF‑7 and PC‑3 cells were stained as a pattern of CK+/EpCAM+/CD45−. 
b White blood cells (WBCs) were stained as CK−/EpCAM−/CD45+. c The 786‑O cells were stained as CK+/vimentin+/CD45−, whereas WBCs were 
stained as CK−/vimentin ±/CD45+ because of cross‑reactivity of vimentin antibody. The morphologic characteristics and antibody staining pat‑
terns of the tumor cells were unchanged after cryopreservation for 66 days
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Denucleated CAMLs observed in both fresh and frozen RCC 
samples
In both fresh and frozen samples (RCC Patient 1), we 
found a cellular structure resembling a typical CAML in 
morphologic characteristics and antibody staining, but 
lacking a cell nucleus (Fig.  4; Table  2). This type of cel-
lular structure is designated as denucleated CAML since 
it has not been described in the literature. The dimension 
of these denucleated CAMLs varies from 15 to 25  µm 
wide and 35 to 80  µm long. They show morphologic 
diversity, with a long shape and sometimes an elongated 
tail (Fig. 4). We observed a naked, multinuclear nucleus 
close to the denucleated CAML (Fig. 4a), suggesting that 
these atypical cellular fragments may result from a pre-
vious event of cell dissociation. Furthermore, denucle-
ated CAMLs were also recovered from the cryopreserved 
samples (Fig. 4b), showing that both intact and denucle-
ated CAMLs were well preserved by cryopreservation.
Recovery of CTCs in RCC samples processed with and 
without cryopreservation
CTCs have been characterized in the peripheral blood 
of patients with metastatic RCC. To determine whether 
CTCs from RCC patients could be preserved with cryo-
preservation, we identified another stage IV RCC patient 
with clear cell histology and prior nephrectomy with 
bone metastases on systemic therapy (RCC Patient 2). 
In this patient, we identified typical cytokeratin-pos-
itive CTCs. The CTC was defined as a cell with a large 
tumor-like nucleus that stained positive to cytokera-
tin and vimentin and negative to CD45. One individual 
CTC was detected in the fresh blood sample from this 
selected patient. In parallel, one individual CTC plus one 
CTC cluster were detected in the matched frozen sam-
ple. Our results demonstrated that those CTCs organized 
as a cluster are preserved after Ficoll separation, cryo-
preservation, thawing, and CellSieve™ microfiltration. 
The CTCs of the fresh sample expressed high levels of 
cytokeratin with typical intracellular network of filament 
structure, which was also observed in the CTCs from the 
cryopreserved sample (Fig.  5). The anti-vimentin anti-
body showed cross-reactivity with some white blood 
cells, but the anti-cytokeratin antibodies were more spe-
cific for tumor cells with less cross-reactivity with white 
blood cells. Moreover, we observed mitotic figures in the 
CTC cluster. The chromosomes in one CTC nuclei were 
separated into two identical sets, each in its daughter 
nucleus (Additional file  6: Figure S5). Our data suggest 
that our cryopreservation technique is compatible with 
preserving mitotic events, CTC morphologic characteris-
tics, and CTC biomarkers.
Discussion
Analysis of tumor-associated cells in peripheral blood 
offers the advantage of a noninvasive approach to study 
changes in biomarkers associated with chemotherapy, 
tumor recurrence, or tumor treatment. However, many 
CTC technologies require the processing of fresh blood 
samples and are incompatible with cryopreserved sam-
ples, limiting the ability to perform retrospective studies 
on archived samples. This limitation may pose a chal-
lenge in multicenter clinical trials and require a central 
laboratory to process samples on the same day for the 
CTC assays. The assay reproducibility may be adversely 
affected by performing each fresh blood sample individu-
ally or by transportation of specimens between locations. 
Cryopreservation is one of the most commonly used 
methods for storage biologic specimens collected over 
time.
We optimized a cryopreservation work flow com-
patible with detecting tumor-associated cells in stored 
peripheral blood to overcome assay limitations that 
require processing of fresh blood. We showed the fea-
sibility of CellSieve™ technology for isolation and iden-
tification of CTCs and CAMLs from cryopreserved 
samples. Our notable observations include (1) recovery 
of spiked tumor cells lines in cryopreserved peripheral 
blood using the CellSieve™ platform; (2) preservation of 
Table 2 Comparison of RCC patient blood samples processed with or without cryopreservation
CAML cancer-associated macrophage-like cell; RCC renal cell carcinoma
a 7.5 mL of whole blood was processed per tube
b RCC patient 1 died on day 73
Time point Day Typical CAML, cells/tubea Denucleated CAML, cells/tube
Fresh Frozen Fresh Frozen
Tube 1 Tube 2 Mean Tube 3 Tube 1 Tube 2 Mean Tube 3
1 0 14 12 13 13 4 4 4 5
2 40 1 2 1.5 2 2 3 2.5 2
3 60b 3 5 4 4 3 4 3.5 3
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Fig. 3 Representative images of cancer‑associated macrophage‑like cells (CAMLs) detected in the matched renal cell carcinoma samples (RCC 
patient 1) with or without cryopreservation. Whole blood samples were drawn at three time points and subjected to Ficoll separation. The matched 
peripheral blood mononuclear cell samples were processed immediately without cryopreservation (fresh) or processed after cryopreservation 
for 7 days (frozen). The filter‑captured cells were stained with CK8, 18, 19/FITC (green), vimentin/EF615 (red), and CD45/Cyanine5 (magenta). Three 
CAMLs, representing different intensities, are presented for the fresh and frozen samples, respectively. a Representative images of typical CAMLs 
detected in the fresh samples. b Representative images of typical CAMLs detected in the frozen samples
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Fig. 4 Denucleated cancer‑associated macrophage‑like cells (CAMLs) detected in the fresh and frozen renal cell carcinoma samples (RCC patient 1). 
a Fresh sample without cryopreservation. A naked multinuclear nucleus, which might be dissociated from the original CAML, is indicated with a red 
arrow. b Frozen sample after cryopreservation for 7 days. To better show structural details in nuclei, we used a light-blue color for DAPI fluorescence 
channel. The small round cells are white blood cells; the round-shaped structures within the denucleated CAMLs may represent white blood cells that 
were adhered to the filter pores and overlapped with the denucleated CAMLs
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cellular morphologic characteristics and markers in cryo-
preserved samples from patients with metastatic RCC; 
and (3) preservation of CTC and CAML enumerations in 
samples cryopreserved up to 66 days at −80 °C.
When evaluating our observations, we found limita-
tions to the present investigation. First, we analyzed 1 CTC 
microfiltration platform, and the cryopreservation proce-
dure may not be compatible with other antigen-dependent 
or antigen-independent cell capture methods. Second, 
although we evaluated breast, prostate, and kidney cancer 
cell lines, we analyzed CTCs and CAMLs only in samples 
from patients with kidney cancer. The DMSO concentra-
tion or Ficoll separation may not be compatible with all 
types of cancer diseases, and further study is required to 
determine whether the cryopreservation procedure is suit-
able for other cancers. Third, we did not extend the study 
beyond 60 days, and the impact of storage beyond this time 
point may or may not have effect on enumeration assays.
Cryopreservation of PBMCs allows phenotypical and 
genetic assays to be performed in batches at a central 
laboratory and minimize assay variation. We have dem-
onstrated that the CellSieve™ system is compatible with 
Ficoll separation and cryopreservation for detection 
of CTCs and CAMLs. Investigators have previously 
reported that CTCs can be recovered from cryopre-
served PBMC samples [7, 9, 16]; however, it was unclear 
whether CAMLs can be recovered from cryopreserved 
PBMC sample. To our knowledge, we are the first to 
report that CAMLs can be separated by Ficoll method, 
cryopreserved for future use, and retrieved after thaw-
ing samples stored up to 60 days at −80 °C. In our Ficoll 
separation, CAMLs segregate to the interphase between 
Ficoll and plasma, where PBMCs and CTCs are located. 
CAMLs may have similar density to other mononuclear 
cells, such as lymphocytes and CTCs, allowing them to be 
enriched through Ficoll separation, and use of a microfil-
tration system can isolate cells on the basis of pore size. 
These enriched cells are suspended in cryoprotectant 
medium, which contains DMSO to reduce cell lysis asso-
ciated with ice crystal formation. Preliminary analysis on 
the signal intensities of CKs between fresh and frozen 
CAMLs are similar, however, the CAML sample size is 
not large enough to draw definitive conclusions.
We observed from the matched samples that the freeze/
thaw process has no adverse effect on morphologic char-
acteristics and the biomarkers of RCC-associated cells. 
a





Merged                 Nucleus (DAPI)          CK8,18,19 (FITC)          Vimentin (EF615)          CD45 (Cyanine5) 
Fig. 5 Detection of Circulating tumor cells (CTCs) in the matched fresh and frozen renal cell carcinoma samples (RCC patient 2). A CTC is defined 
as a nucleated cell positive for both CKs (green) and vimentin (red) but negative for CD45 (magenta). a Fresh peripheral blood mononuclear cell 
sample from a selected patient with renal cell carcinoma, without cryopreservation. b Frozen peripheral blood mononuclear cell sample from the 
same patient with renal cell carcinoma, with cryopreservation for 7 days. The top row shows a cluster of CTCs with one cell in mitosis
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Although we did not observe statistically significant 
changes in enumeration of spiked breast and prostate cell 
lines, further study is required to evaluate whether our 
cryopreservation process is compatible with other tumor 
types. Furthermore, during the course of investigation, 
we also found denucleated CAMLs in frozen samples 
from a patient with RCC, consistent to fresh samples. The 
denucleated CAMLs resemble typical CAMLs closely in 
morphologic characteristics and staining patterns except 
for a lack of nuclei. However, the importance of these 
structures is undefined.
Conclusions
Tumor-associated cells can be recovered successfully 
from cryopreserved PBMC samples with CellSieve™ 
microfiltration. The morphologic features, biomarkers, 
and enumeration of tumor-associated cells are preserved 
in cryopreserved specimens. Application of CellSieve™ 
microfiltration for detection of tumor-associated cells 
in cryopreserved PBMC samples allows the biobanking 
of samples to be processed in batches, to minimize inte-
rassay variations, and also enables large-scale, long-term 
retrospective and epidemiologic analyses in selected 
cancer populations.
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